Open-Label, Single-Arm, Multicenter Study to Evaluate the Rheumatological Tolerability of Letrozole as an Adjuvant Breast Cancer Treatment in Postmenopausal Women Who Are Intolerant and Discontinue Anastrozole Due to Grade 2-3 Arthralgia-Myalgia.

Trial Profile

Open-Label, Single-Arm, Multicenter Study to Evaluate the Rheumatological Tolerability of Letrozole as an Adjuvant Breast Cancer Treatment in Postmenopausal Women Who Are Intolerant and Discontinue Anastrozole Due to Grade 2-3 Arthralgia-Myalgia.

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Letrozole (Primary)
  • Indications Early breast cancer
  • Focus Adverse reactions
  • Acronyms REAL
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 01 Feb 2011 Actual end date changed from Oct 2009 to Jun 2009 as reported by ClinicalTrials.gov.
    • 11 Nov 2009 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.
    • 11 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top